share_log

Ocugen | 8-K: Ocugen Provides Business Update with Second Quarter 2024 Financial Results

Ocugen | 8-K: Ocugen Provides Business Update with Second Quarter 2024 Financial Results

Ocugen | 8-K：Ocugen提供2024年第二季度财务业绩的最新业务情况
美股SEC公告 ·  2024/08/09 01:09

Moomoo AI 已提取核心信息

Ocugen reported Q2 2024 financial results, highlighting progress in its gene therapy programs. The company is actively dosing patients in OCU400 Phase 3 trial for retinitis pigmentosa and has completed dosing in the third cohort of OCU410 Phase 1/2 trial for geographic atrophy. The FDA approved an expanded access program for OCU400, marking it as the first gene therapy candidate for RP to receive such approval.Financial results showed operating expenses of $16.6M for Q2 2024, down from $24.0M in Q2 2023. The company reported a net loss of $0.04 per share, compared to $0.10 in the prior year. Cash position stood at $16.0M as of June 30, 2024. Subsequently, Ocugen raised $32.6M through a public offering, extending its cash runway into Q3 2025.The company continues to advance its pipeline, with OCU410 preliminary data expected later this year. The Phase 3 liMeliGhT trial for OCU400 includes 150 participants and is powered at over 95% assuming a 50% responder rate. Ocugen is actively pursuing strategic partnerships to support its novel modifier gene therapies globally.
Ocugen reported Q2 2024 financial results, highlighting progress in its gene therapy programs. The company is actively dosing patients in OCU400 Phase 3 trial for retinitis pigmentosa and has completed dosing in the third cohort of OCU410 Phase 1/2 trial for geographic atrophy. The FDA approved an expanded access program for OCU400, marking it as the first gene therapy candidate for RP to receive such approval.Financial results showed operating expenses of $16.6M for Q2 2024, down from $24.0M in Q2 2023. The company reported a net loss of $0.04 per share, compared to $0.10 in the prior year. Cash position stood at $16.0M as of June 30, 2024. Subsequently, Ocugen raised $32.6M through a public offering, extending its cash runway into Q3 2025.The company continues to advance its pipeline, with OCU410 preliminary data expected later this year. The Phase 3 liMeliGhT trial for OCU400 includes 150 participants and is powered at over 95% assuming a 50% responder rate. Ocugen is actively pursuing strategic partnerships to support its novel modifier gene therapies globally.
Ocugen报告了2024年第二季度财务业绩，强调了其基因治疗项目的进展。该公司正在积极对参与OCU400 III期试验的视网膜色素变性患者进行给药，并已完成OCU410 I/II期试验第三组的给药。FDA批准了OCU400的扩展访问计划，标志着其成为首个获得此类批准的视网膜色素变性基因治疗候选药物。财务数据显示2024年第二季度营业费用为1660万美元，低于2023年第二季度的2400万美元。该公司报告每股净亏损为0.04美元，相较于之前的0.10美元。截止2024年6月30日，现金余额为1600万美元。随后，Ocugen通过公开发行筹集了3260万美元，延长了其现金支出至2025年第三季度。该公司继续推进其管道，预计将于今年晚些时候公布OCU410的初步数据。OCU400的III期liMeliGht试验包括150名参与者，其主要指标的有效性超过95%，假设应答率为50%。Ocugen正在积极寻求战略合作伙伴，以支持其全球新型修饰基因疗法。
Ocugen报告了2024年第二季度财务业绩，强调了其基因治疗项目的进展。该公司正在积极对参与OCU400 III期试验的视网膜色素变性患者进行给药，并已完成OCU410 I/II期试验第三组的给药。FDA批准了OCU400的扩展访问计划，标志着其成为首个获得此类批准的视网膜色素变性基因治疗候选药物。财务数据显示2024年第二季度营业费用为1660万美元，低于2023年第二季度的2400万美元。该公司报告每股净亏损为0.04美元，相较于之前的0.10美元。截止2024年6月30日，现金余额为1600万美元。随后，Ocugen通过公开发行筹集了3260万美元，延长了其现金支出至2025年第三季度。该公司继续推进其管道，预计将于今年晚些时候公布OCU410的初步数据。OCU400的III期liMeliGht试验包括150名参与者，其主要指标的有效性超过95%，假设应答率为50%。Ocugen正在积极寻求战略合作伙伴，以支持其全球新型修饰基因疗法。
有用
没用

该公告为独立文件：

独立文件1  查看翻译

独立文件2  查看翻译

独立文件3  查看翻译

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    相关股票 相关股票
    代码 迷你走势 最新价
    Moleculin Biotech
    MBRX
    -- 2.1800
    Allogene Therapeutics
    ALLO
    -- 2.040
    CNS Pharmaceuticals
    CNSP
    -- 0.1400
    Tenaya Therapeutics
    TNYA
    -- 1.200
    LEXARIA BIOSCIENCE CORP C/WTS(TO PUR COM)
    LEXXW
    -- 0.3400
    解锁完整榜单
    热门讨论
    特朗普2.0时代开启，全球市场会如何演变？
    🎙️讨论： 1. 关税政策将如何影响美股、黄金、比特币等核心资产的走势？ 2. 在此背景下，有哪些投资机会值得关注？你会如何布局？ 展开
    MicroStrategy 2024年第四季度业绩电话会
    重估中国资产
    继中国开创性的DeepSeek技术推出之后， 华尔街大行重估对中国市场的投资前景。